Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022.

Published on Sep 29, 2021in American Journal of Kidney Diseases8.86
· DOI :10.1053/J.AJKD.2021.05.023
Allison J. Hahr9
Estimated H-index: 9
(NU: Northwestern University),
Mark E. Molitch92
Estimated H-index: 92
(NU: Northwestern University)
Sources
Abstract
The most common cause of kidney failure in the United States and across the world is diabetes mellitus (DM). Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in persons with diabetes, and chronic kidney disease (CKD) further increases overall CVD risk. It is important to individualize glycemic targets for patients to maintain glucose levels that will reduce the development and progression of complications while avoiding hypoglycemia. CKD alters the relationship of glucose levels to measures of long-term control, such as hemoglobin A1c. Medications used to treat DM may need dose adjustments as CKD progresses. Some medications have particular characteristics in patients with CKD. Insulin and sulfonylureas increase the risk of hypoglycemia, some glucagon-like peptide 1 receptor agonists reduce the risk of CVD outcomes, and most sodium/glucose cotransporter 2 inhibitors reduce the risk of CKD and CVD outcomes. Therefore, for the individual patient, changes in medication types and doses may need constant attention as CKD progresses.
đź“– Papers frequently viewed together
2018
References0
Newest
Cited By0
Newest
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.